Detalles de la búsqueda
1.
Dapagliflozin in Patients with Chronic Kidney Disease.
N Engl J Med
; 383(15): 1436-1446, 2020 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32970396
2.
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.
Nephrol Dial Transplant
; 38(5): 1260-1270, 2023 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36301617
3.
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.
J Am Soc Nephrol
; 33(11): 2094-2107, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35977807
4.
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Diabetologia
; 65(7): 1085-1097, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35445820
5.
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
Circulation
; 143(5): 438-448, 2021 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33186054
6.
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Kidney Int
; 101(1): 174-184, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34560136
7.
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial.
Nephrol Dial Transplant
; 37(9): 1647-1656, 2022 08 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34850160
8.
Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease.
Diabetes Obes Metab
; 24(5): 827-837, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34984791
9.
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
J Am Soc Nephrol
; 32(9): 2352-2361, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34272327
10.
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
Eur Heart J
; 42(13): 1216-1227, 2021 03 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-33792669
11.
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
Kidney Int
; 100(1): 215-224, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33878338
12.
Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials.
Diabetes Obes Metab
; 23(8): 1961-1967, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33908683
13.
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
Nephrol Dial Transplant
; 35(9): 1570-1576, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31005993
14.
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Nephrol Dial Transplant
; 35(2): 274-282, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32030417
15.
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Nephrol Dial Transplant
; 35(10): 1700-1711, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32862232
16.
The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.
Diabetes Obes Metab
; 22(4): 549-556, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31742881
17.
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.
Eur Heart J
; 40(11): 880-886, 2019 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28431138
18.
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
Diabetes Obes Metab
; 21(3): 720-725, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30414240
19.
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Nephrol Dial Transplant
; 33(11): 2005-2011, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29370424
20.
Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus.
BMC Nephrol
; 19(1): 146, 2018 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-29929484